Nurix therapeutics to participate in the 22nd annual needham virtual healthcare conference

San francisco, april 11, 2023 (globe newswire) -- nurix therapeutics, inc. (nasdaq: nrix), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today announced that arthur t. sands, m.d., ph.d., nurix's president and chief executive officer, will participate in a fireside chat at the 22nd annual needham virtual healthcare conference on thursday, april 20 at 3:00 p.m. et.
NRIX Ratings Summary
NRIX Quant Ranking